Macrophage inhibiting factor in women with habitual miscarriage in pregnancy following immunocytotherapy

Cover Page

Cite item

Abstract

The aim of our study was to evaluate the macrophage inhibitory factor (MIF) content of in peripheral blood serum, as well as MIF production by mitogen-stimulated cells from whole peripheral blood during pregnancy in women with idiopathic recurrent miscarriage who received immunocytotherapy both prior to and in the first trimester of pregnancy. The study involved 51 women 20 to 40 years old: 10 fertile healthy females beyond pregnancy, 23 women with idiopathic recurrent miscarriage (IRM), 18 women with a physiological course of pregnancy at different stages of gestation (12, in the first trimester; 12, in the second; 9, in third trimester). MIF content was assessed by multiplex analysis using flow fluorometry. Of 23 women with IRM, six lost their pregnancy in the first trimester, 14 women prolonged pregnancy to the full-term resulting into birth of a healthy child; three had premature births at 24 to 35 weeks with a live fetus. There were no intergroup differences in the serum MIF level in control women and in patients with IRM, both beyond and during pregnancy. However, the dynamics of this index during pregnancy, was similar with increase during the II and III trimesters in both groups of women (control and with IRM). During pregnancy, the dynamics of MIF production by mitogen-activated cells from peripheral blood was also similar, except for values in the II trimester: in this period, MIF production in women with IRM was significantly lower, although it was still increased 3 times compared to the 1st trimester (5-fold to controls). In women with physiological pregnancy, the serum MIF levels at 5 to 6 weeks were lower than in women in both IRM subgroups, but there was no difference in MIF content for women with miscarriage and full-term pregnancy. Similarly, there were no differences of MIF contents in the supernates of activated whole blood cells of women at the time of study within groups and between the groups at the same time of examination. It has been shown that ICT has a positive effect on the course and outcomes of pregnancy in women with pregnancy prolonged to full-term. The serum MIF content in women with full-term pregnancy is higher than in women with miscarriage, which is consistent with results of other authors about adverse developmental effects of low serum MIF levels at early pregnancy terms. The results obtained indicate that immunocytotherapy do not regularly promote pregnancy to full term in women with IPV. Therefore, further research is required to find out criteria for administering ICT in treatment of idiopathic recurrent miscarriage.

About the authors

V. V. Vtorushina

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: v_vtorushina@oparina4.ru

PhD (Medicine), Doctor of Clinical Laboratory Diagnostics

117198, Moscow, Acad. Oparin str., 4

Russian Federation

L. V. Krechetova

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: l_krechetova@oparina4.ru

PhD, MD (Medicine), Head, Laboratory of Clinical Immunology

117198, Moscow, Acad. Oparin str., 4

E. V. Inviyaeva

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: e_inviyaeva@oparina4.ru

Inviyaeva Eugenia V. - PhD (Biology), Senior Research Associate, Laboratory of Clinical Immunology

117198, Moscow, Acad. Oparin str., 4

Russian Federation

N. K. Tetruashvili

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: n_tetruashvili@oparina4.ru

PhD, MD (Medicine), Head, Department of Pregnancy Pathology (Department of Therapy and Prevention of Miscarriage)

117198, Moscow, Acad. Oparin str., 4

References

  1. Кречетова Л.В., Николаева М.А., Ванько Л.В., Голубева Е.Л., Зиганшина М.М., Тетруашвили Н.К., Вторушина В.В., Сухих Г.Т. Блокирующий эффект аутологичной сыворотки женщин с привычным невынашиванием беременности // Акушерство и гинекология, 2013. № 3. С. 38-42.
  2. Кречетова Л.В., Николаева М.А., Ванько Л.В., Зиганшина М.М., Вторушина В.В., Хачатрян Н.А., Тетруашвили Н.К., Сухих Г.Т. Продукция цитокинов in vitro мононуклеарными клетками периферической крови при проведении аллоиммунизации у пациенток с привычным выкидышем // Акушерство и гинекология, 2014. № 5. С. 51-56.
  3. Кречетова Л.В., Тетруашвили Н.К., Вторушина В.В., Степанова Е.О., Николаева М.А., Голубева Е.Л., Хачатрян Н.А. Динамика субпопуляционного состава лимфоцитов периферической крови в первом триместре беременности у женщин с привычным выкидышем на фоне проведения иммуноцито-терапии // Акушерство и гинекология, 2015. №. 6. С. 59-66.
  4. Сидельникова В.М. Подготовка и ведение беременности у женщин с привычным невынашиванием: методические рекомендации и клинические протоколы. 3-е изд. М.: МЕДпрессинформ, 2013. 224 с.
  5. Сотникова Н.Ю. Иммунологическая загадка беременности. Иваново: МИК, 2005. 276 с.
  6. Суслов А.П., Коноплева М.В., Третьяков О.Ю. Фундаментальная иммунобиология провоспалительных цитокинов и MIF // Медицинская иммунология, 2006. Т. 8, № 1. С. 5-22..
  7. Патент 2396566 РФ, МПК G01N 33/ 53 (2006.01). Способ определения блокирующего эффекта аутологичной женской сыворотки / Сухих Г.Т., Ванько Л.В., Николаева М.А., Зиганшина М.М., Сидельникова В.М., Кречетова Л.В.; заявитель и патентообладатель ФГБУ НЦ АГП им.В.И.Кулакова, ГОУВПО ММА им. И.М. Сеченова. № 2009116174/15; заявл. 29.04.2009; опубл. 10.08.2010; Бюлл. № 22. 10 с.
  8. Arcuri F., Ricci C., Ietta F., Cintorino M., Tripodi S.A., Cetin I., Garzia E., Schatz F., Klemi P., Santopietro R., Paulesu L. Macrophage migration inhibitory factor in the human endometrium: expression and localization during the menstrual cycle and early pregnancy. Biol. Reprod., 2001, Vol. 64, no. 4, pp. 1200-1205.
  9. Arcuri F., Cintorino M., Carducci A., Papa S., Riparbelli M.G., Mangioni S., Di Blasio A.M., Tosi P., Viganò P. Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction, 2006, Vol. 131, no. 1, pp. 175-182.
  10. Bevilacqua E., Paulesu L., Ferro E.A., Ietta F., Faria M.R., Lorenzon A.R., Costa A.F., Martucci M. Review: putative roles for the macrophage migratory inhibitory factor at the maternal fetal interface. Placenta, 2014, Vol. 35 Suppl., pp. S51-S56.
  11. Cardaropoli S., Ietta F., Romagnoli R., Rolfo A., Paulesu L., Todros T. Lower macrophage migration inhibitory factor concentrations in maternal serum before pre-eclampsia onset. J. Interferon Cytokine Res., 2014, Vol. 34, no/ 7, pp. 537-542.
  12. Comba C., Bastu E., Dural O., Yasa C., Keskin G., Ozsurmeli M., Buyru F., Serdaroglu H. Role of inflammatory mediators in patients with recurrent pregnancy loss. Fertil. Steril., 2015, Vol. 104, no. 6, pp. 1467-1474.e1.
  13. Pearce B.D., Garvin S.E., Grove J., Bonney E.A., Dudley D.J., Schendel D.E., Thorsen P. Serum macrophage migration inhibitory factor in the prediction of preterm delivery. Am. J. Obstet. Gynecol., 2008, Vol. 199, no. 1, pp. 46.e1-e6.
  14. Viganò P., Cintorino M., Schatz F., Lockwood C.J., Arcuri F. The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal-maternal interface. Semin. Immunopathol., 2007, Vol. 29, no. 2, pp. 135-150.
  15. Yamada H., Kato E., Morikawa M., Shimada S., Saito H., Watari M., Minakami H., Nishihira J. Decreased serum levels of macrophage migration inhibition factor in miscarriages with normal chromosome karyotype. Hum. Reprod., 2003, Vol. 18, pp. 616-620.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Vtorushina V.V., Krechetova L.V., Inviyaeva E.V., Tetruashvili N.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Свидетельство о регистрации СМИ ПИ № 77 - 11525 от 04.01.2002 выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies